지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 525 - 534 (10page)
이용수
초록· 키워드
오류제보하기
Purpose: Standard treatment for cases of non-small cell lung cancer (NSCLC) exhibiting acquired drug resistance includes tumorrebiopsy, epidermal growth factor receptor (EGFR) mutation testing (e.g., for T790M mutations), and the subsequent administrationof third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, rebiopsies are typically invasive, costly, and occasionallynot feasible. Therefore, the present study aimed to assess rebiopsy procedures by analyzing real-world data collectedby the ASTRIS study of patients with resistant NSCLC. Materials and Methods: The present study used statistical models to evaluate data collected by the ASTRIS trial (NCT02474355)conducted at Yonsei Cancer Center, including the rebiopsy success rate, incidence of T790M mutations in collected tissue andplasma samples, and association of administered osimertinib treatment efficacy. Results: In a total of 188 screened patients, 112 underwent rebiopsy. An adequate tumor specimen was obtained in 95 of thesepatients, the greatest majority of whom (43.8%) were subjected to bronchoscopy. T790M mutations were detected in 53.3% of successfullyEGFR-tested rebiopsy samples. A total of 88 patients received osimertinib treatment, and the objective response rate andmedian progression-free survival time was 44.3% and 32.7 weeks, respectively, among the treated patients overall, but 57.8% and45.0 weeks, and 35.2% and 20.4 weeks among patients who exhibited T790M-positive tissue (n=45) and plasma (n=54) samples, respectively. Conclusion: Approximately 60% of patients in the analyzed real-world cohort were eligible for tissue rebiopsy upon NSCLC progression. Osimertinib activity was higher in patients in whom T790M mutations were detected in tissues rather than in plasmasamples.
목차
등록된 정보가 없습니다.
참고문헌 (28)
참고문헌 신청
Riely GJ / 2015 / EGFR : the paradigm of an oncogene-driven lung cancer / Clin Cancer Res 21:2221~2226
Costanzo R / 2013 / Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations : current evidence and future perspectives / Expert Rev Anticancer Ther 13:1207~1218
Melosky B / 2014 / Review of EGFR TKIs in metastatic NSCLC, including ongoing trials / Front Oncol 4:244
Camidge DR / 2014 / Acquired resistance to TKIs in solid tumours : learning from lung cancer / Nat Rev Clin Oncol 11:473~481
Westover D / 2018 / Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors / Ann Oncol 29(suppl_1):i10~19
Costanzo R / 2013 / Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations : current evidence and future perspectives / Expert Rev Anticancer Ther 13:1207~1218
Melosky B / 2014 / Review of EGFR TKIs in metastatic NSCLC, including ongoing trials / Front Oncol 4:244
Camidge DR / 2014 / Acquired resistance to TKIs in solid tumours : learning from lung cancer / Nat Rev Clin Oncol 11:473~481
Westover D / 2018 / Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors / Ann Oncol 29(suppl_1):i10~19
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer
Cancer Research and Treatment
2023 .01
-
Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
Cancer Research and Treatment
2022 .10
-
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Journal of Pathology and Translational Medicine
2015 .01
-
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Journal of Pathology and Translational Medicine
2016 .01
-
Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in NSCLC
Cancer Research and Treatment
2024 .07
-
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Cancer Research and Treatment
2018 .01
-
Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
Journal of Korean Medical Science
2016 .01
-
Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group
Journal of Pathology and Translational Medicine
2019 .01
-
Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer
Cancer Research and Treatment
2024 .01
-
Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
Cancer Research and Treatment
2019 .01
-
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Cancer Research and Treatment
2019 .01
-
Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Comprehensive Cancer Panel Sequencing Defines Genetic Diversity and Changes in the Mutational Characteristics of Pancreatic Cancer Patients Receiving Neoadjuvant Treatment
Gut and Liver
2019 .01
-
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cancer Research and Treatment
2021 .01
-
Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance
Investigative and Clinical Urology
2021 .01
-
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea
Cancer Research and Treatment
2020 .01
-
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Cancer Research and Treatment
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0